3,4-二氯苯乙酸甲酯 | 6725-44-6

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二氯苯乙酸甲酯
• 中文别名: 3,4-二氯苯基乙酸甲酯；二氯苯乙酸甲酯
• 英文名称: methyl 2-(3,4-dichlorophenyl)acetate
• 英文别名: methyl 3,4-dichlorophenylacetate；(3,4-dichloro-phenyl)-acetic acid methyl ester
• CAS: 6725-44-6
• 化学式: C₉H₈Cl₂O₂
• mdl: MFCD00800680
• 分子量: 219.067
• InChiKey: FWVOAIHAIWHHDM-UHFFFAOYSA-N

物化性质

• 熔点：
  25-27
• 沸点：
  314.25°C (rough estimate)
• 密度：
  1.54-1.542

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Name:	Methyl 3 4-Dichlorophenylacetate 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	6725-44-6

Section 1 - Chemical Product MSDS Name:Methyl 3 4-Dichlorophenylacetate 99% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6725-44-6	Methyl 3,4-Dichlorophenylacetate	99%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6725-44-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8Cl2O2
Molecular Weight: 218.96

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6725-44-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 3,4-Dichlorophenylacetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 6725-44-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6725-44-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6725-44-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氯苯乙酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 2-(3,4-二氯苯基)-哌嗪
  参考文献：
  名称：

  Synthesis and NK1/NK2 binding activities of a series of diacyl-substituted 2-arylpiperazines

  摘要：

  The synthesis and binding affinity for hNK(1) and hNK(2) receptors of a series of diacyl substituted 2-aryl piperazines are described. SAR evaluation led to the racemic derivative 11g as an apparent dual inhibitor. Chiral chromatographic separation of 11g led to the observation that NK1 activity was shown by one enantiomer (13a) and NK2 activity was shown by the other enantiomer (13b). X-ray crystallographic analysis of the crystalline di-BOC derivative of the NK2, active piperazine (15) showed that the 2R configuration was associated with NK2 activity. Further derivatization indicated that dual NK1/NK2 activity could be built into the 2R series. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00645-5
• 作为产物：
  描述：

  3,4-二氯苯乙酸 以 甲醇 、 乙酸乙酯 为溶剂， 生成 3,4-二氯苯乙酸甲酯
  参考文献：
  名称：

  Aryl and biaryl compounds having MCH modulatory activity

  摘要：

  本发明的其中一个实施例提供了一类新颖的化合物，作为MCH受体的拮抗剂，制备这类化合物的方法，包含一个或多个此类化合物的药物组合物，制备包含一个或多个此类化合物的药物制剂的方法，以及治疗、预防或改善与MCH受体相关的一个或多个疾病的方法。下面展示了一个说明性的创新化合物：1

  公开号：

  US20030092715A1

文献信息

• Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation
  作者：Jiahui Tng、Junxian Lim、Kai-Chen Wu、Andrew J. Lucke、Weijun Xu、Robert C. Reid、David P. Fairlie

  DOI：10.1021/acs.jmedchem.0c00230

  日期：2020.6.11

  active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e

  在多发性骨髓瘤，白血病和淋巴瘤的临床试验中，AR-42是组蛋白脱乙酰基酶（HDAC）的口服活性抑制剂。它几乎没有氢键供体和受体，但是是手性的2-芳基丁酸酯，可能易于消旋。我们报道了非手性AR-42类似物，其包含通过季碳原子连接的环烷基，对人类I类HDAC的效力提高了40倍（例如，JT86，IC 500.7 nM，HDAC1），对五种人类癌细胞系的细胞毒性增加了25倍，而对正常人类细胞的毒性降低了多达70倍。JT86在促进MM96L黑色素瘤细胞中乙酰化组蛋白H4积累方面比racAR-42强9倍。分子模型和结构-活性之间的关系支持四氢吡喃与HDAC1的结合，而四氢吡喃则是对酶表面水的疏水屏蔽。这种有效的I类HDAC抑制剂可在AR-42活跃的疾病（癌症，寄生虫感染，炎性疾病）中显示出益处。
• [EN] CHIMERIC COMPOUNDS AND METHODS OF MANAGING NEUROLOGICAL DISORDERS OR CONDITIONS<br/>[FR] COMPOSÉS CHIMÉRIQUES ET MÉTHODES DE GESTION DE TROUBLES OU D'ÉTATS NEUROLOGIQUES
  申请人：UNIV EMORY

  公开号：WO2020176513A1

  公开（公告）日：2020-09-03

  This disclosure relates to chimeric compounds and methods for managing neurological conditions. In certain embodiments, the compound comprises a chemical structure of a monoamine reuptake inhibitor conjugated to a chemical structure of a histone deacetylase inhibitor. In certain embodiments, this disclosure relates to methods of treating or preventing a neurological disorder, mental disorder or depression comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.

  这份披露涉及嵌合化合物及用于管理神经状况的方法。在某些实施例中，该化合物包含一个单胺再摄取抑制剂的化学结构，与一个组蛋白去乙酰化酶抑制剂的化学结构结合。在某些实施例中，本披露涉及治疗或预防神经障碍、精神障碍或抑郁症的方法，包括向需要此的受试者施用本处披露的化合物的有效量。
• Practical Application of the Aqueous ‘Sulfonyl-Azide-Free’ (SAFE) Diazo Transfer Protocol to Less α-C–H Acidic Ketones and Esters
  作者：Dmitry Dar’in、Grigory Kantin、Mikhail Krasavin

  DOI：10.1055/s-0039-1690613

  日期：2019.11

  Abstract The earlier described ‘sulfonyl-azide-free’ (‘SAFE’) protocol for diazo transfer to CH-acidic 1,3-dicarbonyl compounds (and their similarly activated congeners) has been extended to the less reactive monocarbonyl substrates, which previously required a separate activation step. Formylation in situ, followed by the addition of an optimized amount of the ‘SAFE cocktail’ (obtained by mixing sodium

  抽象的 较早描述的重氮转移至CH酸性1,3-二羰基化合物（及其类似活化的同类物）的``无磺酰叠氮''（``SAFE''）方案已扩展至反应性较低的单羰基底物，以前需要单独的激活步骤。甲酰化原位，然后加入“安全鸡尾酒”的优化量的（通过混合叠氮化钠，碳酸钾，和得到米导致期望的重氮化合物的形成，这是由分离-carboxybenzenesulfonyl氯化物在水中）提取的产率中等至极好，并且在大多数情况下，无需额外纯化。 较早描述的重氮转移至CH酸性1,3-二羰基化合物（及其类似活化的同类物）的``无磺酰叠氮''（``SAFE''）方案已扩展至反应性较低的单羰基底物，以前需要单独的激活步骤。甲酰化原位，然后加入“安全鸡尾酒”的优化量的（通过混合叠氮化钠，碳酸钾，和得到米导致期望的重氮化合物的形成，这是由分离-carboxybenzenesulfonyl氯化物在水中）提取的产率中等至极好，并且在大多数情况下，无需额外纯化。
• [EN] INDOLE ANTIVIRAL COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS ANTIVIRALES A BASE D'INDOLE ET PROCEDES CORRESPONDANTS
  申请人：UNIV MICHIGAN

  公开号：WO2005034943A1

  公开（公告）日：2005-04-21

  The present invention provides novel chemical compounds and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.

  本发明提供了新颖的化合物和它们的使用方法。具体来说，本发明提供了吲哚衍生物（例如如公式（I）所示）和相关化合物，以及使用吲哚衍生物和相关化合物作为治疗剂治疗多种疾病的方法，包括与病毒感染和心血管疾病相关的疾病。
• Guide to enantioselective dirhodium(II)-catalyzed cyclopropanation with aryldiazoacetates
  作者：Kathryn M. Chepiga、Changming Qin、Joshua S. Alford、Spandan Chennamadhavuni、Timothy M. Gregg、Jeremy P. Olson、Huw M.L. Davies

  DOI：10.1016/j.tet.2013.04.075

  日期：2013.7

  Catalytic enantioselective methods for the generation of cyclopropanes have been of long standing pharmaceutical interest. Chiral dirhodium(II) catalysts prove to be an effective means for the generation of diverse cyclopropane libraries. Rh2(R-DOSP)4 is generally the most effective catalyst for asymmetric intermolecular cyclopropanation of methyl aryldiazoacetates with styrene. Rh2(S-PTAD)4 provides

  用于生成环丙烷的催化对映选择性方法长期以来一直是制药业的兴趣所在。手性二铑 (II) 催化剂被证明是生成各种环丙烷库的有效手段。Rh 2 ( R -DOSP) 4通常是重氮乙酸甲酯与苯乙烯的不对称分子间环丙烷化反应最有效的催化剂。Rh 2 ( S -PTAD) 4提供高水平的邻位取代芳基重氮乙酸酯的对映体诱导。不太成熟的 Rh 2 ( R -BNP) 4对 Rh 2 ( R-DOSP) 4和 Rh 2 ( S -PTAD) 4在催化 3-甲氧基取代的重氮基乙酸芳基酯的高度对映选择性环丙烷化反应中。苯乙烯的取代对环丙烷化的不对称诱导仅具有中等影响。